3,577 Shares in Glaukos Corporation (NYSE:GKOS) Bought by XTX Topco Ltd

Key Points

• XTX Topco Ltd made an investment of approximately $352,000 in Glaukos Corporation by acquiring 3,577 shares during the 1st quarter, as reported in a recent SEC filing.
• Glaukos Corporation reported a 29.7% year-over-year increase in revenue, amounting to $124.12 million for the last quarter, with an EPS of ($0.24) which beat expectations.
• The stock currently holds a Moderate Buy average rating from analysts, with a target price of $127.42 after several analysts adjusted their price objectives.

XTX Topco Ltd bought a new stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,577 shares of the medical instruments supplier's stock, valued at approximately $352,000.

A number of other institutional investors have also added to or reduced their stakes in GKOS. Bessemer Group Inc. grew its position in shares of Glaukos by 133.9% in the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after buying an additional 158 shares during the last quarter. Whipplewood Advisors LLC grew its position in shares of Glaukos by 3,957.1% in the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 277 shares during the last quarter. First Horizon Advisors Inc. grew its position in shares of Glaukos by 72.9% in the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after buying an additional 159 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Glaukos by 583.9% in the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 327 shares during the last quarter. Finally, CoreCap Advisors LLC grew its position in shares of Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Stock Performance

Shares of GKOS traded up $2.43 during trading hours on Wednesday, hitting $91.77. The stock had a trading volume of 984,680 shares, compared to its average volume of 965,319. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The firm has a 50-day moving average price of $96.92 and a 200 day moving average price of $104.76. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of -55.62 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm had revenue of $124.12 million during the quarter, compared to analysts' expectations of $115.49 million. During the same period in the previous year, the business posted ($0.52) EPS. The business's revenue was up 29.7% compared to the same quarter last year. As a group, research analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. UBS Group lifted their target price on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Piper Sandler lowered their target price on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research note on Tuesday, April 15th. Stifel Nicolaus lowered their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. BTIG Research reiterated a "buy" rating on shares of Glaukos in a research note on Monday, July 14th. Finally, William Blair upgraded shares of Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $127.42.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.